Advertisement
Screener

AMNEAL PHARMACEUTICALS, INC. (AMRX) Medium-term Notes, Current

2.8 / 5 stars · 68/120 Roast Me

AMNEAL PHARMACEUTICALS, INC. Medium-term Notes, Current

AMNEAL PHARMACEUTICALS, INC. (AMRX) had Medium-term Notes, Current of $21.43 million as of 2018-06-30, per its 10-Q filed 2018-08-09.

Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current

us-gaap:MediumtermNotesCurrent · last filed 2018-08-09

  • 2018-06-30: Medium-term Notes, Current $21.43M.
  • 2017-12-31: Medium-term Notes, Current $14.17M.
Period endMedium-term Notes, Current
2018-06-30$21.43M
10-Q · filed 2018-08-09
2017-12-31$14.17M
10-Q · filed 2018-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liquidia Corp (LQDA)United States$6.347B51.23
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
Alkermes plc. (ALKS)$6.844B132.74
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07